Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bas Oldenburg
The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Therapeutic drug monitoring of methotrexate in patients with Crohn's disease
1 INTRODUCTION Methotrexate (MTX) intramuscularly (IM) or subcutaneously (SC) is effective as maintenance therapy in patients with mild to moderate–severe Crohn's disease (CD)1, 2 The efficacy of MTX monotherapy for remission induction is not clearly established and high-quality studies are lacking.2, 3 In clinical practice, MTX is occasionally used for induction of remission in mild CD, alone or combined with prednisolone or budesonide.4 For maintenance treatment, the choice between MTX and...
Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases - the longer the less? Authors' reply
INVITED EDITORIAL Johannes P. D. Schultheiss, Johannes P. D.
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
Summary Background Both vedolizumab and ustekinumab can be considered for the treatment of Crohn’s disease (CD) when anti‐TNF treatment fails. However, head‐to‐head trials are currently not available or planned. Aim To compare vedolizumab and ustekinumab in Crohn´s disease patients in a prospective registry specifically developed for comparative studies with correction for confounders.
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Summary Background Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). Aim To evaluate effectiveness, safety and use of tofacitinib in daily practice. Methods UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands.
Early Discontinuation of Anti-TNF-alpha in Women With IBD
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel In This Article Abstract and Introduction Abstract Background: In rheumatoid arthritis and psoriasis female sex has been shown to be associated with discontinuation of anti-tumour necrosis factor-α (TNF-α) therapy.
Earlier discontinuation of TNF‐α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects - Schultheiss - - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Summary Background In rheumatoid arthritis and psoriasis female sex has been shown to be associated with discontinuation of anti‐tumour necrosis factor‐α (TNF‐α) therapy. Aim To retrospectively assess the association between sex and TNF‐α drug persistence in patients with inflammatory bowel disease (IBD). Methods All IBD patients on anti‐TNF‐α therapy with a minimum follow‐up of 12 months in a single tertiary centre were identified.
The elusive case of human intraepithelial T cells in gut homeostasis and inflammation
Abstract The epithelial barrier of the gastrointestinal tract is home to numerous intraepithelial T cells (IETs). IETs are functionally adapted to the mucosal environment and are among the first adaptive immune cells to encounter microbial and dietary antigens. They possess hallmark features of tissue-resident T cells: they are long-lived nonmigratory cells capable of rapidly responding to antigen challenges independent of T cell recruitment from the periphery.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bas
Contact Bas, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack